Multi-Indication Assets

GlycoMantra has developed a few high-affinity galectin-3 antagonists (GM100 series) useful for various indications (see Drug Pipeline). GlycoMantra’s CAR-T asset is based on a novel concept of personalized “off-the-shelf” cellular immunotherapy for kidney cancer. GlycoMantra’s other asset is small molecule drug for metastatic colorectal cancer.